Clinically Validated Probiotics
Complex Journey from Innovation to Patient impact
AI is in Every Pharma Strategy Deck
Electronic Logs - The next phase of execution maturity in pharma
Elevating Drug Safety
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
University of Lincoln, UK
Senior Lecturer, School of Pharmacy
Ishwar Singh is a Senior Lecturer in Biological Chemistry at the School of Pharmacy University of Lincoln Prior to Lincoln he had held many prestigious fellowships such as the Alexander von Humboldt fellowship Germany and Senior Research Fellowship DANIDA Denmark and CSIR India He is an organic chemist He has developed bioconjugations for DNA RNA and polymer modifications in water He is currently...
Articles
Accelerating the Medical Writing Process with Automation From research to publication
The Pharmaceutical and Life Sciences industry has seen a constant growth in the need for medical writing The global medical writing market was valued at US billion in and is expected to reach US billion in growing at a Compound Annual Growth Rate CAGR of per cent Patents have been expiring
Research Insights
Development of a New Radiofluorinated Quinoline Analog for PET Imaging of Phosphodiesterase 5 (PDE5) in Brain
Abstract Phosphodiesterases PDEs are enzymes that play a major role in cell signalling by hydrolysing the secondary messengers cyclic adenosine monophosphate cAMP andor cyclic guanosine monophosphate cGMP throughout the body and brain Altered cyclic nucleotidemediated signalling has been associated with a wide array of disorders including neurodegener
Case Studies
Applying Data Mining Techniques To Medical Time Series: An Empirical Case Study
Abstract One of the major challenges in the medical domain today is how to exploit the huge amount of data that this field generates To do this approaches are required that are capable of discovering knowledge that is useful for decision making in the medical field Time series are data types that are common in the medical domain and require specialized analy
Techno Trends
Grünenthal Developed First-of-its-Kind Resiniferatoxin for Osteoarthritis Pain
Grnenthal developed firstofitskind nonopioid medicine resiniferatoxin RTX for the pain associated with osteoarthritis OA of the knee
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Evolution of eCTD from version 1 to 4
Gouspasha is a seasoned professional with 12 years of experience in the pharmaceutical industry, specializing in eCTD (Electronic Common Technical Document) publishing and submission. With a strong focus on regulatory compliance and efficient document management, Gouspasha ensures seamless and timely submissions. Dedicated to maintaining the highest standards of quality and accuracy, Gouspasha remains committed to staying current with evo0lving industry trends and regulatory requirements.
Perspectives on the Vaccine Industry
As a Senior Consultant in Bioprocessing Strategy at Merck with over 14 years of
international biopharma experience, Josephine Cheng focuses on vaccine and mRNA market segments, where she translates strategies into market initiatives to enable the utilisation of best-in-class technologies and transforms industry insights into sustainable business strategies.
Josephine obtained Bachelor's and Master's degrees in Bio-resource's; Agriculture from the National Taiwan University.
Mussel-inspired Bio-adhesives
Amisha Raikar is a highly motivated individual with a strong educational background in the field of pharmaceutics. She completed her Bachelor of Pharmacy (B-Pharm) from Goa University in 2022, which laid the foundation for her journey into the pharmaceutical industry. Building upon her undergraduate degree, Amisha decided to pursue Master of Pharmacy (M-Pharm) in pharmaceutical science and formulation development. Recognising the importance of expanding her skill set beyond the technical aspects of pharmaceuticals, she embarked on a Postgraduate Diploma in International Business Management from the Indira Gandhi National Open University (IGNOU). Amisha's passion for learning and her desire to contribute to the field of pharmaceuticals has fueled her interest in pursuing a Ph.D. With her strong educational background, practical experience, and an eagerness to pursue further studies, Amisha Raikar is poised to make significant contributions to the field of pharmaceuticals through her future endeavours, such as a Ph.D. program.
Schedule M guideline: Revision and its nationwide implementation
Dr. M. Aamir Mirza is working as an Assistant Professor in the Department of Pharmaceutics, Jamia Hamdard, an NIRF Rank 1 institute and a NAAC ‘A+” grade deemed to be University. He has a multifaceted career portfolio adorned with both industry and academic accomplishments. During his industry stay he became a seasoned scientist and dealt with challenging NCE/NDA development. He is on advisory boards of some international research-based companies of India, New Zealand and Europe. Academics and Research being close to his heart, he has published more than 110 manuscripts in the journals of international repute and has been granted 02 Indian patent and filed for 04. He has contributed several chapters in books published by reputed authors like Elsevier and Bentham. He is amongst the very few scientists globally who has an expertise in Humic substances research. A well-travelled scientist; he has delivered scientific addresses in countries like USA, Austria, Japan, Netherlands, Turkey, Estonia, Spain and Russia. He has been Elite Fellow at University of Malaya (Malaysia) for the last 5 years where he takes classes on the topics related to industrial pharmacy.
Lipid Based Drug Delivery Systems
Venu Madhav Katla working as Professor in Department of Pharmaceutics and having over 15 years of teaching and research experience. He had more than 15 research and review publications. He is having 10 national as well as international presentations in his credit. He guided around 25 M.Pharm and one Ph.D student (Pursuing).
Sridhar Babu Gummadi working as Professor and having over 18 years of teaching and research experience. He is having more than 20 research and review publications. Had 10 national as well as international presentations in his credit. He had one patent and one book as publication. He guided around 35 M.Pharm and 4 Ph.D students (Pursuing).
Somnath De working as Professor and have over 15 years of teaching and research experience. He had more than 20 research and review publications. He is having 10 national as well as international presentations in his credit. He filed one patent. He guided around 24 MPharm and 4 Ph.D students (Pursuing).
press releasesRead more...
Chai Discovery Announces Collaboration with Roche in AI-Driven Drug Discovery
Chai Discovery the AI company building a computeraided design suite for proteinbased therapeutics today announced a collaboration with Roche to use Chais AI models and platform in a number of drug discovery programs across its therapeutic areas
PharmAla Signs Agreement and Initiates R&D with Corealis Pharma for GMP Manufacturing of its patented ALA-002 Drug Product
PharmAla Biotech Holdings Inc a biotechnology company focused on the research development and manufacturing of MDXXclass molecules including its proprietary LaNeo MDMA announces that it has signed an agreement with Corealis Pharma Inc Corealis a GMPcompliant contract development
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
HUTCHMED China Limited announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of autoimmune hemolytic anemia AIHA Sovleplenib is a novel selective oral spleen tyrosine kinase Syk inhibitor
Abbott and Novo expand partnership to launch Plosbrio® broadening access to semaglutide for advanced diabetes care across Asia Pacific
Abbott the global healthcare leader and Novo a global leader in treatments for serious chronic diseases announced an expanded strategic collaboration to increase access to originator semaglutide for people living with type diabetes across Asia Pacific Under the agreement Abbott will commercialise
Zuellig Pharma Strengthens Clinical Sourcing Capabilities in China through Strategic Acquisition
Zuellig Pharma a leading healthcare solutions company in Asia announced the strategic acquisition of a specialized clinical supply facility in Hangzhou China strengthening its clinical sourcing capabilities to better support domestic and international clinical trials
Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
Teva Pharmaceutical Industries Ltd and Samsung Bioepis Co Ltd today announced that they have entered into a license and commercialization agreement for two FDAapproved immunology biosimilars infliximababda a biosimilar to Remicade infliximab and ETICOVO etanerceptykro a biosimilar to Enbrel etanerc...
EventsRead more...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
10 - 11
Nov 2026Extractables & Leachables Europe
Parkhotel Schӧnbrunn, Vienna,...
11 - 13
Nov 2026Frontiers in Cancer Science 2026
One Farrer Hotel,1 Farrer Park...
11 - 12
Nov 2026Medical Device Project and Portfolio Management
Chicago, IL, USA
16 - 17
Nov 2026Analytics for Smarter Decisions in Pharma
London, UK
24 - 25
Nov 2026BioPharma Deals - The Survival Series
Munich, Germany
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
24 - 25
Nov 2026BioPharma Deals Conference 2026
Science Congress Center, Munic...
LATEST NEWSRead more...
Johnson & Johnson Receives Approval for RYBREVANT FASPRO to Treat Advanced Head and Neck Cancer
Johnson Johnson has received accelerated approval from the US Food and Drug Administration FDA for RYBREVANT FASPRO amivantamab and hyaluronidaselpuj to treat adults with recurrent or metastatic head and neck squamous cell carcinoma HNSCC
Boehringer Ingelheim Enters into Partnership with SBP Group to Advance Next-Generation Cancer Therapies
Boehringer Ingelheim and Sino Biopharmaceutical SBP Group have entered into a multiprogram partnership to develop potential nextgeneration cancer treatments using antibodydrug conjugate ADC and Tcell engager TcE technologies
MindWalk Partners with Teva to Support Antibody Discovery Using AI
MindWalk has entered into a multiyear agreement with Teva Pharmaceuticals Australia to support antibody discovery and design optimisation using AI technology ReefIQ is MindWalks biological context platform for the life sciences sector powered by its HYFT technology The technology
CStone Enters into Collaboration with Kimia Therapeutics to Advance Clinical Development of Novel Oncology Drug
CStone Pharmaceuticals has entered into a clinical development collaboration with USbased Kimia Therapeutics to advance a potential firstinclass drug candidate targeting the DNA damage response DDR pathway which plays an important role in the survival of solid tumour cells
DKSH and The Baker Company Partner to Expand Cell Culture and Microbiology Research
DKSH Business Unit Technology has entered into an exclusive distribution agreement with The Baker Company to make its Baker Ruskinn range of controlledenvironment technologies available to laboratories across Thailand The partnership aims to improve access to equipment used in cell culture tissue c...
Fresenius Enters into Agreement with WuXi Biologics to Expand Biosimilars Pipeline
Fresenius has entered into an exclusive development agreement with WuXi Biologics to expand its biosimilars pipeline and strengthen its biopharmaceutical business The partnership will give Fresenius access to WuXi Biologics capabilities in biologics research development and manufacturing
